
Thalia Papayannopoulou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4561004/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A comparative encyclopedia of DNA elements in the mouse genome. Nature, 2014, 515, 355-364.	13.7	1,444
2	Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. Nature, 1990, 344, 309-313.	13.7	354
3	Mouse regulatory DNA landscapes reveal global principles of cis-regulatory evolution. Science, 2014, 346, 1007-1012.	6.0	244
4	Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood, 2004, 103, 1580-1585.	0.6	210
5	Anti–VLA4/VCAM-1—Induced Mobilization Requires Cooperative Signaling Through the kit/mkit Ligand Pathway. Blood, 1998, 91, 2231-2239.	0.6	209
6	A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. Nature Immunology, 2017, 18, 654-664.	7.0	139
7	Human Platelets Display High-Affinity Receptors for Thrombopoietin. Blood, 1997, 89, 1896-1904.	0.6	138
8	Functional footprinting of regulatory DNA. Nature Methods, 2015, 12, 927-930.	9.0	123
9	The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization. Blood, 2003, 101, 4739-4747.	0.6	107
10	Bone marrow homing: the players, the playfield, and their evolving roles. Current Opinion in Hematology, 2003, 10, 214-219.	1.2	87
11	Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major. Molecular Therapy - Methods and Clinical Development, 2018, 10, 313-326.	1.8	83
12	In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. Blood, 2016, 128, 2206-2217.	0.6	76
13	HDAd5/35++ Adenovirus Vector Expressing Anti-CRISPR Peptides Decreases CRISPR/Cas9 Toxicity in Human Hematopoietic Stem Cells. Molecular Therapy - Methods and Clinical Development, 2018, 9, 390-401.	1.8	63
14	2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood, 2015, 126, 89-93.	0.6	62
15	Defect in glycosylation of erythrocyte membrane proteins in congenital dyserythropoietic anaemia type II (HEMPAS). British Journal of Haematology, 1984, 56, 55-68.	1.2	60
16	Therapeutic targeting and rapid mobilization of endosteal HSC using a small molecule integrin antagonist. Nature Communications, 2016, 7, 11007.	5.8	51
17	In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. Journal of Clinical Investigation, 2018, 129, 598-615.	3.9	43
18	IL-1α and Complement Cooperate in Triggering Local Neutrophilic Inflammation in Response to Adenovirus and Eliminating Virus-Containing Cells. PLoS Pathogens, 2014, 10, e1004035.	2.1	42

#	Article	IF	CITATIONS
19	Cytokine Prestimulation as a Gene Therapy Strategy: Implications for Using the MDR1 Gene as a Dominant Selectable Marker. Blood, 1997, 89, 146-154.	0.6	35
20	A Combined InÂVivo HSC Transduction/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice. Molecular Therapy - Methods and Clinical Development, 2018, 8, 52-64.	1.8	33
21	Hematopoietic Stem/Progenitor Cell Mobilization: A Continuing Quest for Etiologic Mechanisms. Annals of the New York Academy of Sciences, 1999, 872, 187-199.	1.8	32
22	Increase in Circulating SDFâ€1 after Treatment with Sulfated Glycans. Annals of the New York Academy of Sciences, 2001, 938, 48-53.	1.8	32
23	Brief Report: A Differential Transcriptomic Profile of Ex Vivo Expanded Adult Human Hematopoietic Stem Cells Empowers Them for Engraftment Better than Their Surface Phenotype. Stem Cells Translational Medicine, 2017, 6, 1852-1858.	1.6	28
24	Integrating HDAd5/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies. Molecular Therapy - Methods and Clinical Development, 2018, 9, 142-152.	1.8	28
25	Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors. Molecular Therapy, 2019, 27, 2195-2212.	3.7	28
26	InÂVivo Hematopoietic Stem Cell Transduction. Hematology/Oncology Clinics of North America, 2017, 31, 771-785.	0.9	26
27	Hemopoietic lineage commitment decisions: in vivo evidence from a transgenic mouse model harboring μLCR-βpro-LacZ as a transgene. Blood, 2000, 95, 1274-1282.	0.6	24
28	The macrophage contribution to stress erythropoiesis: when less is enough. Blood, 2016, 128, 1756-1765.	0.6	24
29	Stage-specific functional roles of integrins in murine erythropoiesis. Experimental Hematology, 2014, 42, 404-409.e4.	0.2	23
30	High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Advances, 2019, 3, 2883-2894.	2.5	19
31	Safe and efficient inÂvivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors. Molecular Therapy - Methods and Clinical Development, 2022, 24, 127-141.	1.8	19
32	Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements. JCI Insight, 2020, 5, .	2.3	17
33	Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood, 2021, 138, 1540-1553.	0.6	16
34	A haemoglobin switching activity modulates hereditary persistence of fetal haemoglobin. Nature, 1984, 309, 71-73.	13.7	13
35	Patterns of spectrin transcripts in erythroid and non-erythroid cells. Journal of Cellular Physiology, 1990, 144, 287-294.	2.0	12
36	GM 58/8: a monoclonal antibody that identifies a new lineage-specific determinant expressed by myeloid progenitors (CFU-GM) and their progeny. British Journal of Haematology, 1984, 58, 147-158.	1.2	11

Thalia Papayannopoulou

#	Article	IF	CITATIONS
37	Deletion of Dicer in late erythroid cells results in impaired stress erythropoiesis in mice. Experimental Hematology, 2014, 42, 852-856.e1.	0.2	9
38	Reappraising the role of α5 integrin and the microenvironmental support in stress erythropoiesis. Experimental Hematology, 2020, 81, 16-31.e4.	0.2	9
39	Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. Blood Advances, 2021, 5, 1239-1249.	2.5	9
40	Anti–VLA4/VCAM-1—Induced Mobilization Requires Cooperative Signaling Through the kit/mkit Ligand Pathway. Blood, 1998, 91, 2231-2239.	0.6	9
41	Stains for Inclusion Bodies. CRC Critical Reviews in Clinical Laboratory Sciences, 1974, 5, 70-72.	1.0	7
42	Anomalous cell surface structure of sickle cell anemia erythrocytes as demonstrated by cell surface labeling and endo-β-galactosidase treatment. Journal of Supramolecular Structure and Cellular Biochemistry, 1981, 17, 289-297.	1.4	5
43	Control of fetal globin expression in man: new opportunities to challenge past discoveries. Experimental Hematology, 2020, 92, 43-50.	0.2	5
44	Human hemoglobin switching: Insights from studies of erythroid cultures. Journal of Cellular Physiology, 1982, 113, 145-149.	2.0	4
45	Biologic effects of thrombopoietin, the Mpl ligand, and its therapeutic potential. Cancer Chemotherapy and Pharmacology, 1996, 38, S69-S73.	1.1	4
46	Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α4–Integrin Deficient NOD Mouse. Cells, 2020, 9, 2597.	1.8	4
47	Investigating the Barrier Activity of Novel, Human Enhancer-Blocking Chromatin Insulators for Hematopoietic Stem Cell Gene Therapy. Human Gene Therapy, 2021, 32, 1186-1199.	1.4	4
48	In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques. Blood, 2020, 136, 46-47.	0.6	3
49	Introduction of Two Simultaneous Mutations By Genome Editing Greatly Enhances the Accumulation of the Endogenous Fetal Hemoglobin in Human Normal Erythroid Cells. Blood, 2017, 130, 947-947.	0.6	2
50	Cytokine Prestimulation as a Gene Therapy Strategy: Implications for Using the MDR1 Gene as a Dominant Selectable Marker. Blood, 1997, 89, 146-154.	0.6	2
51	α4-Integrin deficiency in human CD34+ cells engenders precocious erythroid differentiation but inhibits enucleation. Experimental Hematology, 2022, 108, 16-25.	0.2	2
52	CD4+c-Met+ltgα4+ T cell subset promotes murine neuroinflammation. Journal of Neuroinflammation, 2022, 19, 103.	3.1	2
53	Cytokine Exposure Changes the Hierarchy of Molecular Pathway Usage in Bone Marrow Homing Blood, 2005, 106, 3161-3161.	0.6	1
54	Hematopoietic Stem/Progenitor Cells (HSPC) Mobilization Parameters in Patients Chronically Treated with the CD49d Blocking Antibody Natalizumab Blood, 2007, 110, 177-177.	0.6	1

4

THALIA PAPAYANNOPOULOU

#	Article	IF	CITATIONS
55	Insights into the Biology of Mobilized Cells through Innovative Treatment Schedules of the CXCR4 Antagonist AMD3100 Blood, 2007, 110, 2229-2229.	0.6	1
56	Gi Protein Signals Are Required for BM Homing of Hemopoietic Progenitor Cells, and Cooperate with Alpha4-Intergrin and Endothelial Selectins Blood, 2004, 104, 2183-2183.	0.6	0
57	In Vivo Expansion of Transduced Human Erythroid Cells Using an Mpl-Based Cell Growth Switch Blood, 2004, 104, 2100-2100.	0.6	0
58	Superior Bone Marrow Homing of G-CSF Mobilized Hematopoietic Progenitor Cells (HPC) - A Home Run Blood, 2005, 106, 471-471.	0.6	0
59	b1 Integrin Deficiency in Both Erythroid Cells and Their Microenvironment Does Not Affect Basal Erythropoiesis but Critically Impairs Survival and Erythroid Response to Phenylhydrazine-Induced Stress in Adult Mice. Blood, 2008, 112, 3567-3567.	0.6	0
60	Regulatory Reprogramming of Erythropoiesis By DNMT3A Mutation. Blood, 2018, 132, 4343-4343.	0.6	0
61	Thalassemia Gene Therapy By In Vivo Transduction of Mobilized Hematopoietic Stem Cells (HSCs) with an Integrating Hybrid Adenovirus Vector System. Blood, 2018, 132, 2193-2193.	0.6	0
62	Combining HPFH Mutations in Human Adult HSCs to Enhance Reactivation of Fetal Hemoglobin. Blood, 2019, 134, 2246-2246.	0.6	0
63	The Glucocorticoid Receptor-Dependent Stress Response in Human Erythropoiesis Is BCL11A-Dependent. Blood, 2021, 138, 939-939.	0.6	0